Clinical Trial Update: Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment [Phase 2]

View source ↗

Summary

A Phase 2 trial tested a three-drug combination of bortezomib, liposomal doxorubicin, and rituximab in relapsed or refractory diffuse large B-cell lymphoma. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Doxil (liposomal doxorubicin) (liposomal doxorubicin)
• Rituxan (rituximab) (rituximab)
• Velcade (bortezomib) (bortezomib)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2014-07-21